Literature DB >> 19344210

Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect.

Anton A Volkov1, Natal'ya S Kruglova, Mariya I Meschaninova, Alya G Venyaminova, Marina A Zenkova, Valentin V Vlassov, Elena L Chernolovskaya.   

Abstract

Small interfering RNAs (siRNAs) are considered as potent agents for specific gene silencing; however, nuclease sensitivity of siRNA limits their biomedical applications. Till date, no universal methodology has been developed to improve the nuclease resistance of siRNA, preserving low toxicity and high activity. In this study, we proposed an algorithm for the site-specific modification of siRNAs based on the mapping of their nuclease-sensitive sites in the presence of serum followed by the incorporation of 2'-O-methyl analogs of ribonucleotides at the identified positions of cleavage. We found that the protection of nuclease-sensitive sites considerably enhanced nuclease resistance of siRNA and only slightly reduced the efficiency of silencing. Modification of all nuclease-sensitive sites prolonged the duration of the silencing effect of the siRNA compared to nonmodified, partially modified, or randomly modified siRNA of the same sequence. This study showed that the targeted chemical modification of nuclease-sensitive sites could provide highly efficient siRNA-based therapeutics for the control of disease-related genes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344210     DOI: 10.1089/oli.2008.0162

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  23 in total

Review 1.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

2.  Probing the inherent stability of siRNA immobilized on nanoparticle constructs.

Authors:  Stacey N Barnaby; Andrew Lee; Chad A Mirkin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-19       Impact factor: 11.205

3.  2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.

Authors:  Sherry Y Wu; Xianbin Yang; Kshipra M Gharpure; Hiroto Hatakeyama; Martin Egli; Michael H McGuire; Archana S Nagaraja; Takahito M Miyake; Rajesha Rupaimoole; Chad V Pecot; Morgan Taylor; Sunila Pradeep; Malgorzata Sierant; Cristian Rodriguez-Aguayo; Hyun J Choi; Rebecca A Previs; Guillermo N Armaiz-Pena; Li Huang; Carlos Martinez; Tom Hassell; Cristina Ivan; Vasudha Sehgal; Richa Singhania; Hee-Dong Han; Chang Su; Ji Hoon Kim; Heather J Dalton; Chandra Kovvali; Khandan Keyomarsi; Nigel A J McMillan; Willem W Overwijk; Jinsong Liu; Ju-Seog Lee; Keith A Baggerly; Gabriel Lopez-Berestein; Prahlad T Ram; Barbara Nawrot; Anil K Sood
Journal:  Nat Commun       Date:  2014-03-12       Impact factor: 14.919

4.  Evaluation of siRNA Stability and Interaction with Serum Components Using an Agarose Gel-Based Single-Molecule FRET Labeling Method.

Authors:  Martina Tuttolomondo; Henrik J Ditzel
Journal:  Methods Mol Biol       Date:  2021

Review 5.  Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine.

Authors:  Zhihang Chen; Balaji Krishnamachary; Jesus Pachecho-Torres; Marie-France Penet; Zaver M Bhujwalla
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-10-23

6.  Simple FRET Electrophoresis Method for Precise and Dynamic Evaluation of Serum siRNA Stability.

Authors:  Martina Tuttolomondo; Henrik J Ditzel
Journal:  ACS Med Chem Lett       Date:  2020-01-17       Impact factor: 4.345

7.  Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.

Authors:  Jesper B Bramsen; Jørgen Kjems
Journal:  Front Genet       Date:  2012-08-20       Impact factor: 4.599

8.  A Comparison of Target Gene Silencing using Synthetically Modified siRNA and shRNA That Express Recombinant Lentiviral Vectors.

Authors:  P V Spirin; D Baskaran; P M Rubtsov; M A Zenkova; V V Vlassov; E L Chernolovskaya; V S Prassolov
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

9.  Non-coding RNAs: Bridging Biology and Therapy.

Authors:  Daniel P C Shreve; David R F Carter
Journal:  J RNAi Gene Silencing       Date:  2009-05-22

10.  Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo.

Authors:  Shunsuke Wada; Satoshi Obika; Masa-Aki Shibata; Tsuyoshi Yamamoto; Moeka Nakatani; Tetsuji Yamaoka; Hidetaka Torigoe; Mariko Harada-Shiba
Journal:  Mol Ther Nucleic Acids       Date:  2012-09-18       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.